Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprietary precision gene editing technology. Our technology utilizes novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to improve the precision, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy (Associate Professor at UCSF and discoverer of anti-CRISPR proteins) and Dr. David Rabuka (former Founder and CSO of Redwood Biosciences) with the mission of bringing precision genetic therapies to the clinic.